Compare Frozen Shoulder Treatment Options

There is no single treatment that is best for every person or every stage of frozen shoulder. The most appropriate option depends on what is limiting the shoulder:

ACM is designed for carefully selected patients whose assessment confirms true adhesive capsulitis with a substantial capsular component. The program addresses the contracted capsule, the muscular restriction surrounding the joint and the rehabilitation required to convert restored passive movement into active function.

Traditional manipulation under anesthesia, or MUA, is an established capsular treatment for selected patients with frozen shoulder. It is commonly performed under general anesthesia. The surgeon moves the anesthetized shoulder through restricted ranges to stretch and release the contracted capsule. The movement produced on the operating table is passive: the procedure moves the joint, but it does not itself retrain protective muscle guarding, activate weakened muscles, lengthen chronically shortened tissues or teach the patient to control the newly available range.

Conventional MUA pathways therefore depend on postoperative physiotherapy and home exercise to translate passive movement into active, functional movement. Published protocols frequently begin physiotherapy soon after manipulation, but repeated appointments and continued rehabilitation can still be required while the patient works to recover muscular control and maintain the capsular range.

Muscle guarding deserves specific attention. A published case series found that active muscle guarding may be a major contributor to restricted movement in some patients who present with the classical features of frozen shoulder.¹¹ Conventional MUA does not include ACM’s defined neuromuscular soft-tissue treatment before the capsular procedure, its repeated Day 2 muscular treatment or its immediate hourly active-rehabilitation sequence.

General anesthesia removes conscious protective responses and can reduce muscular tone and end-range feedback, depending on the anesthetic agents used. This permits large passive ranges, but force must remain within the patient’s tissue tolerance. Recognized MUA complications include fracture, dislocation, rotator-cuff or labral injury and nerve injury. ACM uses monitored IV sedation with maintained independent breathing and muscular tonicity, and a dedicated assistant continuously stabilizes the humeral head while the orthopedic surgeon mobilizes the joint. This direct humeral-head stabilization is a defined ACM safety step rather than a standardized element described across conventional MUA protocols.

ACM includes an orthopedic-surgeon-controlled capsular mobilization, but it is not a stand-alone manipulation. It adds the following coordinated stages:

The distinction is the complete peri-procedural sequence. Traditional MUA first releases the capsule and leaves muscular recovery and active control to postoperative rehabilitation. ACM treats the muscular and capsular components in succession, measures active unassisted movement and begins active rehabilitation within 30 minutes. The objective is not simply to create passive range on the table, but to help the patient actively use and maintain that movement as early as possible.

Arthroscopic capsular release is keyhole surgery, commonly performed under general anesthesia. The shoulder capsule sits deep within the joint. The surgeon creates small portal incisions through the skin and soft tissue, passes an arthroscope and surgical instruments into the joint, and surgically divides selected contracted capsular tissue under direct visualization. It can improve pain and range of motion in refractory frozen shoulder, but the patient must recover from the surgical portals and released tissue while completing postoperative rehabilitation.

ACM addresses capsular restriction without arthroscopic portals or surgical cutting. The capsule is prepared through controlled distension, then mobilized by the orthopedic surgeon while the humeral head is stabilized and the VibraCussor assists progressive adhesion separation. ACM also includes muscular preparation before the capsular procedure and immediate structured rehabilitation afterward.

The movement created during arthroscopic release is passive joint excursion. The operation directly treats the capsule, but it does not provide a defined pre-procedure treatment for muscle guarding, shortened tissues, weakness or impaired activation. Active functional movement must be developed afterward through physiotherapy and home rehabilitation. This can require repeated visits over an extended period while the shoulder also heals from surgery. Persistent or recurrent stiffness can occur, so postoperative movement and rehabilitation remain important.

General anesthesia has a different risk profile from ACM’s local capsular anesthesia with monitored IV sedation. ACM maintains independent breathing and muscular tonicity and adds neuromuscular soft-tissue treatment before the capsular procedure, again on Day 2 and throughout the active home-recovery program.

The principal pathway differences are:

Hydrodilatation, also called hydrodistension, uses an image-guided injection to expand the shoulder capsule. Injectate commonly includes saline, local anesthetic and corticosteroid. Technique, volume and the intended capsular endpoint vary. Some protocols preserve the capsule and rely on distension followed by exercise. Other protocols continue until fluid ruptures the capsule and escapes through a rupture site.

Hydrodilatation can improve pain, disability and external rotation for some patients, particularly in the short term. The 2026 systematic review found substantial variation in technique and low-certainty evidence for greater external rotation at twelve weeks compared with corticosteroid injection alone, without significant differences in pain, disability, abduction or forward flexion.⁴

Capsular distension is not the same as surgeon-controlled multidirectional release. When hydrodilatation preserves the capsule, any further capsular improvement depends on the effect of the distension and the exercises or physiotherapy that follow. When rupture occurs, fluid exits through the rupture path; the injection does not allow an orthopedic surgeon to progressively mobilize every restricted direction and control how each region is released.

Hydrodilatation also does not include a defined treatment for protective muscle guarding, shortened tissues, weakness or impaired activation. Any immediate movement created by distension is not automatically active, functional movement. The patient must use follow-up exercise or physiotherapy to address muscular control, while any residual capsular restriction can continue to limit progress.

ACM uses controlled capsule-preserving distension as preparation rather than as the complete treatment. The program then continues with orthopedic-surgeon-controlled multidirectional mobilization, VibraCussor-assisted adhesion separation, neuromuscular treatment and immediate active rehabilitation.

An intra-articular corticosteroid injection is intended to reduce inflammation and pain. Current evidence supports short-term symptom and movement improvement, particularly during the earlier and more inflammatory stage of frozen shoulder. The 2025 British Elbow and Shoulder Society pathway recommends considering glenohumeral steroid injection for short-term symptom control and reports that the benefit beyond three months is uncertain.¹

A corticosteroid injection does not mechanically separate established adhesions or a contracted capsule and does not provide a defined treatment for protective muscle guarding, shortened tissues or weakness. When it helps, the benefit is symptom control rather than mechanical release. Relief can last for weeks or several months, varies by patient and can be followed by a return of symptoms as the medication effect decreases. A temporary post-injection flare can also occur.

Repeated corticosteroid injections are not an unlimited long-term solution. The appropriate number and interval are individualized according to the joint, diagnosis, dose, response and patient’s medical risks. Published reviews describe local risks that include post-injection flare, infection, tendon injury or rupture and adverse effects on cartilage; tendon and cartilage effects can be influenced by dose and frequency.¹³

The key comparison is direct: a corticosteroid injection can reduce inflammation and pain, but it does not release the scar tissue that mechanically restricts the joint. ACM addresses the contracted capsule and adhesions while also treating the muscular component and beginning immediate active rehabilitation.

ACM is intended for appropriately selected patients whose principal limitation includes significant capsular restriction. A minute dose of corticosteroid can be included during ACM capsular preparation when clinically appropriate, while the local anesthetic, capsular expansion, controlled mobilization, muscular treatment and immediate rehabilitation perform separate roles within the complete program.

Physiotherapy and appropriate manual therapy can help maintain movement, improve strength, reduce pain and support everyday function. They are important conservative options and can also identify shoulder conditions such as rotator-cuff irritation, tendinopathy or impingement that can mimic or accompany frozen shoulder.

Treatment intensity should match the irritability of the shoulder. Gentle movement within tolerance helps preserve function, while repeated forceful stretching into sharp or shooting pain can increase pain and aggravate an irritable shoulder. A staged program should progress the intensity of exercise and manual treatment as the shoulder becomes less irritable.¹⁴

Physiotherapy can address muscle activity, guarding, strength and movement, but it usually does so progressively over repeated sessions and home practice. When a contracted capsule remains the principal mechanical restriction, exercises and manual treatment do not provide an immediate mechanical capsular release. The capsule can continue to block movement even as the muscular component improves.

The muscular component distinguishes ACM in both timing and intensity. In clinic-documented cases, selected patients demonstrate substantial active, unassisted range-of-motion improvement after one approximately 20- to 30-minute neuromuscular soft-tissue session. The clinic records the movement before and after treatment and measures applicable ranges with a digital inclinometer. The treatment is designed to reduce guarding, strengthen weakened muscles, lengthen shortened tissues and improve active control immediately before the capsular procedure, and it is repeated on Day 2. Individual changes reflect how much of that patient’s restriction is muscular versus capsular.

ACM then directly addresses the capsular restriction and provides a self-directed lengthening and strengthening program that can be performed in brief sessions throughout the day without relying on multiple in-person physiotherapy appointments each week. This sequence is designed to convert the capsular movement achieved during the procedure into active functional movement as early as possible.

Shoulder artery embolization is an emerging catheter-based treatment. An interventional radiologist introduces a catheter through an artery and embolizes abnormal vascularity associated with inflammation and pain around the shoulder.

Published studies report improvements in pain, function and range of motion over follow-up periods measured in months. Current evidence is based largely on observational cohorts, and recent reviews call for further randomized controlled trials.⁵

Embolization targets abnormal vascularity and the inflammatory contribution to pain. It does not mechanically separate scar tissue that has already formed, mobilize a contracted capsule or provide a defined treatment for muscle guarding and weakness. When established adhesions and capsular contracture are the principal restrictions, reducing the inflammatory signal does not remove the existing mechanical block.

ACM is directed at a stiffness-dominant shoulder when the clinical assessment confirms substantial capsular contracture and adhesions. Embolization can represent a different pathway for selected patients whose symptoms are pain-predominant and whose interventional-radiology assessment supports a vascular target.

Frozen shoulder can improve naturally, but the time course and completeness of recovery vary. Symptoms can continue for months or years, and some patients retain pain, stiffness or functional limitation.

A systematic review of untreated frozen shoulder found some improvement over one to four years but did not find evidence supporting inevitable progression through defined stages to complete recovery without treatment.⁶

Observation can be reasonable when symptoms are manageable, function is improving and the patient is comfortable with a gradual recovery. During this period, tolerable movement and strengthening help preserve muscle activity and function.

ACM offers an intervention pathway for appropriately selected patients who want the contracted capsule addressed directly and whose assessment confirms that the anticipated benefit justifies the procedure and rehabilitation commitment.

ACM may be the most appropriate option when:

Published research supports the descriptions of conventional frozen shoulder treatments and the individual clinical principles incorporated into ACM. The complete ACM sequence is specific to Frozen Shoulder Specialists. The studies below support treatment characteristics, conventional outcomes and clinical decision-making rather than a direct head-to-head trial of the complete ACM program against every alternative.